Post-surgical Pain Clinical Trial
Official title:
A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty
Verified date | October 2018 |
Source | Adynxx, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objectives of this study are to evaluate the safety and analgesic efficacy of a single preoperative intrathecal administration of AYX1 Injection in patients undergoing unilateral total knee arthroplasty.
Status | Completed |
Enrollment | 210 |
Est. completion date | December 19, 2017 |
Est. primary completion date | October 23, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Scheduled to undergo primary unilateral TKA with spinal anesthesia for painful osteoarthritis without congenital knee pathology - American Society of Anesthesiologists Physical Status Classification System = 3 - Medically stable as determined by the Investigator based on pre-study medical history, physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG) findings - Body Mass Index of 18-45 kg/m2 - Stable medical regimen for at least 1 week before randomization - Able to read and understand study instructions in English, and willing and able to comply with all study procedures Exclusion Criteria: - More than 2 other current focal areas of pain, any pain areas greater in intensity than the target knee, or any other active chronic pain conditions that would compromise operative knee pain evaluation - Inflammatory arthridities (e.g., rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis), with the exception of clinically stable/non-active gout that does not affect the knee and does not interfere with walking - Surgery in either knee within 3 months prior to randomization, or surgery in either knee greater than 3 months prior to randomization with residual symptoms that would interfere with post-TKA study assessments; use of cryoneurolysis (including Iovera) on the current operative knee region within the 6 months prior to randomization and/or at any time through the duration of the study - Planned use of general anesthesia or potent inhalational agents, peripheral nerve block (e.g., femoral nerve block), neuroaxial (intrathecal or epidural) opioids, preoperative extended release/long acting opioids, or any use of ketamine preoperatively and/or at any time through the duration of the study - Use of more than 40 mg per day (on average) of oral morphine or its equivalent within 1 month prior to randomization - Use of gabapentin or pregabalin within 1 week prior to randomization or planned use post-operatively through Day 28 - Use of systemic corticosteroids (IV or oral) within 3 months prior to randomization through Day 28; planned use of intra-articular steroid injections in the operative knee from the time of randomization through Day 28 - Current neurologic disorder, which could confound the assessment of pain (e.g., Parkinson's, Multiple Sclerosis) - Untreated or inadequately treated (in the opinion of the Investigator) active depression - Mini Mental State Exam score < 24 at screening - History of alcohol-related complications within 1 year of randomization including, but not limited to, alcoholic withdrawal seizures, hallucinations, delirium tremens or detoxification treatment - Known or suspected history of illicit drug use within 1 year before randomization, or current or planned use of marijuana (including medical approved use) within 1 month before randomization and/or through the duration of the study - Any confirmed malignancy within the past year, with the exception of basal cell carcinoma or uncomplicated or stable skin cancers documented to not require further or immediate treatment - Women who are pregnant or nursing - Previous participation in any study involving AYX1 Injection |
Country | Name | City | State |
---|---|---|---|
United States | Alabama Orthopedic Center | Birmingham | Alabama |
United States | The Ohio State University Wexner Medical Center | Columbus | Ohio |
United States | CORE Orthopaedic Medical Center | Encinitas | California |
United States | Antria, Inc. | Indiana | Pennsylvania |
United States | Mississippi Sports Medicine | Jackson | Mississippi |
United States | Pensacola Research Consultants | Pensacola | Florida |
United States | Arizona Research Center | Phoenix | Arizona |
United States | Shoals Medical Trials | Sheffield | Alabama |
United States | Phoenix Clinical Research | Tamarac | Florida |
Lead Sponsor | Collaborator |
---|---|
Adynxx, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean pain with walking during the 15 meter walk test Day 7 to Day 28 | Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 15 meter walk test during the outpatient period from Day 7 to Day 28 | 7-28 days post-surgery | |
Secondary | Percentage of subjects with NRS pain score = 4 during the 15 meter walk at Day 90 | Percentage of subjects with the Numerical Rating Scale (NRS) pain score = 4 during the 15 meter walk at Day 90 | at 90 days post-surgery | |
Secondary | Mean pain rating (NRS) at rest Day 7 to Day 28 | Mean pain rating with the Numerical Rating Scale (NRS) at rest Day 7 to Day 28 | 7-28 days post-surgery | |
Secondary | Total use of postoperative opioid medications (morphine equivalents) post-discharge to Day 90 | Total use of postoperative opioid medications (morphine equivalents) post-discharge to Day 90 | post-hospital discharge through 90 days post-surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04988490 -
Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
|
||
Terminated |
NCT01694199 -
A Multicenter, Randomized, Sham-Controlled, Double-Blinded Study to Evaluate the Analgesic Efficacy and Safety of Pulsed Radiofrequency Energy (PRFE) in Bunionectomy Surgery for the Treatment of Post-Operative Pain
|
N/A | |
Recruiting |
NCT05657704 -
Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol
|
Phase 4 | |
Recruiting |
NCT03421522 -
Intercostobrachial Nerve Sparing to Reduce Post-Surgical Pain
|
N/A | |
Completed |
NCT03730350 -
Perioperative ACT-Based Clinical Hypnosis for Opioid Weaning
|
N/A | |
Completed |
NCT03933124 -
The Effect of Virtual Reality on Post-surgical Pain and Recovery.
|
N/A | |
Completed |
NCT03599089 -
Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients
|
Phase 2 | |
Terminated |
NCT04085237 -
ESP Block for Laparoscopic Nephrectomy Surgeries
|
N/A | |
Completed |
NCT02145221 -
Effects of Music Therapy on the Recovery of Patients Undergoing Spine Surgery
|
N/A | |
Completed |
NCT02523235 -
Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks
|
Phase 4 |